Abstract:Background CD47,knownasintegrin-associatedreceptorprotein,isover-expressed onnon-small-celllungcancer(NSCLC)cells.Itcaninteractwithsignalregulatory protein-a(SIRPa)andinhibitmacrophagephagocytosis.Autophagy,akeyingredient in microenvironment maintenance, plays a critical role in tumorigenesis, tumor development and metastasis. Here, we report a potential approach for NSCLC therapy by targeting both CD47 and autophagy. Background ClusterofDifferentiation(CD47),knownasintegrin-associatedreceptor protein,isover-expressedonnon-small-celllungcancer(NSCLC)cells.Itcaninteract withsignalregulatoryprotein-alpha(SIRPa)andinhibitmacrophagephagocytosis. Autophagy, a key ingredient in microenvironment maintenance, plays a critical role in tumorigenesis, tumor development and metastasis. Here, we report a potential approach for NSCLC therapy by blocking both CD47 and autophagy. Methods A novel fusion protein named SIRPa-Fc was prepared and employed to target CD47onNSCLCcells.Threestandardtechniquesincludingconfocalmicroscope, transmission electron microscope and western blots were used to detect the autophagy in NSCLC cells after CD47 blockade. LDH-release and CFSE staining assay were appliedtodetectthephagocytosisofNSCLCcellsafterblockadeofCD47/autophagy. NSCLC xenograft models were established in BALB/c nude mice to investigate the anti- tumoreffectoftargetingbothCD47andautophagyinNSCLC. Methods A novel fusion protein named SIRPa-Fc was prepared and employed to block CD47onNSCLCcells.Threestandardtechniquesincludingtransmissionelectron microscope, confocal microscope and western blot were used to detect autophagy in NSCLCcellsafterCD47blockade.LDH-releaseandCFSEstainingassaywereapplied todetectthephagocytosisofNSCLCcellsafterblockadeofCD47/autophagy.NSCLC xenograft models were established in BALB/c nude mice to investigate the anti-tumor effectofblockingbothCD47andautophagyinNSCLC. Results WefoundthatblockingCD47couldincreasethephagocytosisandcytotoxicity ofmacrophageagainstNSCLCcells.Duringthisprocess,autophagywastriggered, which was characterized by the three main stages ofautophagic fluxincluding: formation and accumulation ofautophagosomes, fusion ofautophagosomes into lysosomesanddegradationofautophagosomesinlysosomes.Importantly,inhibitionof autophagyinNSCLCcellscouldnotablyenhancetheeffectofCD47blockadeon macrophage-mediatedcytotoxicity,whileco-suppressionofautophagyandCD47 signalingcouldalsoelicitpotentanti-NSCLCefficacyinvivo. Results WefoundthatblockingCD47couldincreasethephagocytosisofmacrophage against NSCLC cells. During this process, autophagy was triggered, which was characterized by the three main stages ofautophagic fluxincluding: formation andaccumulationofautophagosomes,fusionofautophagosomesintolysosomes anddegradationofautophagosomesinlysosomes.Importantly,inhibitionof autophagyinNSCLCcellscouldnotablyenhancetheeffectofCD47blockadeon macrophage-mediatedphagocytosis, whileco-suppressionofautophagyandCD47 signalingcouldalsoelicitenhancedanti-NSCLCefficacyinvivo. Conclusions We demonstrated that autophagy was induced in NSCLC cells after CD47 blockade,whileinhibitionofautophagycouldsignificantlyenhancetheanti-tumor efficacyofCD47blockadeinNSCLCs.Ourdataelucidatedthecriticalroleofautophagy inCD47abolishment-basedNSCLStherapyandhighlightedthepotentialapproachfor thetreatmentofNSCLCbyblockingautophagyandCD47. Legal entity responsible for the study N/A Funding the National Natural Science Foundation ofChina (81573332) Disclosure All authors have declared no conflicts ofinterest.

399P Blocking CD47 and Autophagy for the Therapy of Non-Small-cell Lung Cancer

Targeting Cd47 and Autophagy Elicited Enhanced Antitumor Effects in Non-Small Cell Lung Cancer

Blocking CD47 with Restructured Peptide Nanoparticles for Motivating Phagocytosis to Inhibit Tumor Progression

Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer

Targeting the CD47-SIRPα Signaling Axis: Current Studies on B-cell Lymphoma Immunotherapy

CD47 Masks Pro-Phagocytic Ligands in Cis on Tumor Cells to Suppress Antitumor Immunity

The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment

Novel and Promising Therapeutic Approaches for Glioblastoma: Blocking CD47-SIRPα Axis Alone or Combined with Autophagy Depletion

Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy

Disrupting CD47-SIRPα Axis Alone or Combined with Autophagy Depletion for the Therapy of Glioblastoma.

Facilitating cholangiocarcinoma inhibition by targeting CD47

Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo

Targeting CD47 Enhanced the Antitumor Immunity of PD-L1 Blockade in B-cell Lymphoma.

Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma

CD47 Blockade Triggers T Cell–mediated Destruction of Immunogenic Tumors

Abstract B007: Upregulation of PD-L1 as a mechanism of resistance to CD47 inhibition in non-small cell lung cancer

Dual Blockade of CD47 and HER2 Re-sensitizes Resistant Breast Cancer Cells to Radiation Therapy

Targeting CD47 and Angiogenesis Demonstrates Effective Anti-Tumor Effect in Bladder Cancer

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer

800 Dual targeting of CTLA-4 and CD47 on Treg cells rejuvenates immunity against solid tumors